We observed that the group of E+/+ patients was distinct from E+/− and E−/− patients in the context of tumor aggressiveness (serum AFP-levels (</≥400 ng/mL) and number of HCC nodules). This evidence concerns the gene AFP and hepatocellular carcinoma.